How to address the problem of discarded donor organs

Adoctorflushesadonorkidneyduringatransplantprocedure.BRENDANSMIALOWSKI/AFP/GettyImagesAsIwasgettingr SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We




knowledge

author：focus    Page View：48194
Peter Marks. -- health coverage from STAT
Peter Marks, Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration. Susan Walsh-Pool/Getty Images

Peter Marks wants drug developers to ask more stupid questions.

It’s part of the top Food and Drug Administration official’s plan to reinvigorate gene therapy, a field that has struggled despite significant technological advances. Some companies are shelving programs or going out of business, even when they have promising data. 

advertisement

The problems are numerous: The diseases are often exceptionally rare, limiting the potential market. Manufacturing at commercial quality is complex and expensive. Proving a drug works can be difficult, because there may be too few patients to run a traditional randomized study. 

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： House looks to weaken Medicare negotiation
Next article： In Memoriam: Notable people who died in 2023